FREE WEBINAR - 3 x 20 MINUTE EXPERT SESSIONS
Point-of-Care diagnostic consumable development: Don’t underestimate the importance of biochemistry expertise!
It is without question that the global pandemic has created an explosion in the demand for automated point-of-care consumables. In the face of this demand, the race to launch new innovative diagnostics has never been run at a faster pace.
However, significant challenges remain in translating lab-based assays onto automated high-performance consumables. Foremost among these are the challenges presented by the integration and optimization of biochemistries. Indeed, it is probably the single most underestimated step toward successfully developing and commercializing a diagnostic consumable.
Through three 15-minute segments followed by a Q&A, this educational webinar addresses best practices in overcoming these development challenges by three thought leaders in this field.
Specifically, participants can expect to learn:
- Fundamental elements of the process for successful assay translation through an early design perspective.
- A universal workflow for complex microarray development and performance optimization
- The performance advantages of nanoparticle bioconjugation in point-of-care assay development
Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.
TearLab® Corporation, together with SCHOTT MINIFAB are celebrating an important milestone with the delivery of the 20 millionth microfluidic eye test card from the production line in Melbourne, Australia. The milestone comes as a result of a 13-year contract manufacturing partnership between the two companies, beginning in 2007 with an ambitious microfluidic product development program.
When it comes to managing and mitigating product development risk, there are six guiding principles that are proven to work.
Market leader in microfluidic device manufacture has re-branded from MINIFAB to SCHOTT MINIFAB. The change of name and visual re-brand comes after SCHOTT AG acquired the company in July 2019 and forms one part of an ongoing integration process.
Taking a long-term view at the outset of the cartridge development program is critical for reducing the cost of goods (COGS) when the time inevitably comes to ramp up manufacturing volume.
Are you developing a diagnostic microfluidic product? Validating assay maturity is critical for commercial success.
Edward Wilkinson, Vice President of SCHOTT MINIFAB USA and Head of Strategy, explains why a fully integrated bioscience and engineering approach is the key to risk mitigation.
We are pleased to inform you, our valued customer, that Minifab is very well advanced in its plans to operate during the COVID-19 pandemic. Minifab is built on a culture of innovation. Overcoming the world's most challenging problems is second nature to us.
Our number one priority is always to the health and safety of our workforce. In this unique environment protecting our workforce also protects you - our customer.